Polaryx Therapeutics Inc PLYX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics Gets FDA Fast Track Designations for Its Lead Drug Candidate
Trading Information
- Previous Close Price
- $1.60
- Day Range
- $1.61–1.68
- 52-Week Range
- $1.56–48.91
- Bid/Ask
- $1.61 / $1.77
- Shares Outstanding
- 49.85M
- Market Cap
- $80.25M
- Volume/Avg
- 22,334 / 40,064
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.polaryx.com
Valuation
Metric | PLYX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.54 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | PLYX |
|---|---|
Quick Ratio | 8.45 |
Current Ratio | 8.62 |
Interest Coverage | — |
Quick Ratio
PLYX
Profitability
Metric | PLYX |
|---|---|
Return on Assets (Normalized) | −100.54% |
Return on Equity (Normalized) | −114.11% |
Return on Invested Capital (Normalized) | −114.11% |
Return on Assets
PLYX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|v?rnXF! | LOCK|P>?l | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|>X<vNmv | LOCK|#!@CV | $98B | |||
| Moderna Inc MRNA | LOCK|#r>X!l | LOCK|zfN | $80B | |||
| argenx SE ADR ARGX | LOCK|Q<t$Tl | LOCK|ZS | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&bjZ%! | LOCK|fFV | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!K$JM^< | LOCK|xQ<> | $31B | |||
| Incyte Corp INCY | LOCK|c$?pg>& | LOCK|Rc | $24B | |||
| BioNTech SE ADR BNTX | LOCK|%M%<H>$ | LOCK|J?< | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|?K$sb> | LOCK|yf$h | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|>bBL&X | LOCK|H^ | $16B |